Fulgent Genetics Q3 2026 net loss widens 99% to $13.15 million
FLGT•Fulgent Genetics' third-quarter 2026 net loss widened 99% year over year to $13.15 million, while revenue rose 8% to $90.41 million. The company expects full-year revenue of $330 million to $340 million.
1. Quarterly results
Fulgent Genetics reported third-quarter 2026 revenue of $90.41 million, up 8% year over year, and a net loss of $13.15 million, which widened 99%. CEO Ming Hsieh highlighted momentum in the therapeutics pipeline and continued AI integration into laboratory workflows. The company expects full-year 2026 revenue of $330 million to $340 million.
